$PLTR

Jobs Numbers Set for Release Next Week

The article lists upcoming U.S. and Canada economic releases and scheduled earnings for the week. Key data include U.S. manufacturing and services PMIs, job openings, ADP and the employment report, and initial jobless claims. It also cites quarterly EPS figures for companies such as PLTR, VRTX, MAR, AMD, CAT, LLY, NVO, and COP, among others.

Original reporting
Published Aug 3, 2026, 5:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 3, 2026, 6:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Jobs Numbers Set for Release Next Week — source image
Decision brief

The 30-second read

$PLTRNeutralLow
01

Why it matters

It can help traders plan event risk around jobs-related macro prints and multiple earnings dates, but it does not disclose any new company results, guidance, or policy decisions.

02

Market read

Primary value is event timing for macro and earnings volatility, not new fundamental information.

03

What to watch

Actual market impact will depend on the surprise versus consensus at release time, which this article does not provide.

Relevance 4/10Novelty 2/10Timing: next-week earnings and US/Canada labor and jobs-related releases

Background

The piece is a next-week economic and earnings lookahead, listing scheduled US and Canada data releases and featured earnings names.

Company-level read

Ticker impact

$PLTRNeutralLow confidence
Context

The calendar lists Palantir Q2 EPS of 28 cents versus 13 cents prior-year, but provides no new results or guidance.

Expected impact

Limited immediate impact from this article alone; volatility risk exists only when the actual earnings print arrives.

Evidence & confidence

The text is a next-week preview with no new company-specific event beyond the scheduled earnings reference.

$VRTXNeutralLow confidence
Context

Vertex Q2 EPS is listed as 34 cents versus 32 cents prior-year, presented as a featured earnings item.

Expected impact

No actionable price impact from the preview itself.

Evidence & confidence

The article does not report a new print, guidance change, or management update.

$MARNeutralLow confidence
Context

Marriott Q2 EPS is listed as $3.06 versus $2.65 prior-year in the featured earnings section.

Expected impact

Preview-only, so expected impact is minimal until the actual report.

Evidence & confidence

No new data beyond the calendar-style listing.

$AMDNeutralLow confidence
Context

Advanced Micro Devices is listed for Q3 EPS of $1.35 versus 27 cents prior-year, as part of the Tuesday featured earnings.

Expected impact

Potential volatility around the actual earnings date, but not attributable to this article.

Evidence & confidence

No earnings results, guidance, or management commentary are provided.

$CATNeutralLow confidence
Context

Caterpillar Q2 EPS is listed as $6.25 versus $4.72 prior-year in the featured earnings lineup.

Expected impact

No immediate trading signal from the calendar entry alone.

Evidence & confidence

The article does not report a new print or corporate action.

$MRKNeutralLow confidence
Context

Merck Q2 EPS is listed as a loss of 26 cents versus a gain of $2.13 prior-year, as a featured earnings item.

Expected impact

Trading impact depends on the actual earnings release, not on this preview.

Evidence & confidence

No new results, guidance, or regulatory updates are disclosed.

$LLYNeutralLow confidence
Context

Eli Lilly is listed for Q2 EPS of $6.71 versus $6.31 prior-year in the Wednesday featured earnings.

Expected impact

No actionable impact until the earnings report is released.

Evidence & confidence

The article provides no fresh company event or datapoint beyond the calendar listing.

$NVONeutralLow confidence
Context

Novo Nordisk is listed for Q2 EPS of 81 cents versus 97 cents prior-year in the Wednesday featured earnings.

Expected impact

Limited impact from the preview itself.

Evidence & confidence

No new guidance, trial update, or earnings result is reported.

Market effects

Broad earnings calendar across software, semis, industrials, and healthcare, but without new sector-specific catalysts.

US and Canada macro releases (jobs, claims, GDP, PMI/services) can drive cross-asset risk sentiment.

Limited direct global linkage beyond standard macro and earnings scheduling.

Counterpoint

Because this is only a calendar preview, traders may overreact to the listed prior-year comparisons that are not forecasts or new disclosures.

Key entities

  • U.S. employment report (July)

    Scheduled for Friday, with the article framing it as the key jobs-related event.

  • Initial jobless claims (Aug 1)

    Scheduled for Thursday, a near-term labor-market risk catalyst.

  • Featured earnings (multiple tickers)

    A list of companies expected to report across Monday to Friday.

Related articles

$NVDAMed

Why Are AI Semiconductor Stocks Nvidia, AMD, and Intel Rising in Pre-Market Trading Today, Sept. 16?

Nvidia (NVDA), AMD (AMD), and Intel (INTC) are rising in pre-market trading due to AI chip demand and sector developments. Intel is in talks with SK Hynix (SKHY) about its Ohio facility. Nvidia's CEO will attend a Trump-Xi meeting, potentially impacting its China business. AMD shows strong demand, with Piper Sandler setting a $600 price target. Intel has a $165 target from Melius Research, citing its foundry business.

$MUMed

Why Are Memory Chip Stocks Micron, SanDisk, and SK Hynix Falling in Pre-Market Today, Sept. 10?

Micron (MU), SanDisk (SNDK), and SK Hynix (SKHY) fell in pre-market trading due to profit-taking and Kioxia's comments on memory prices. Kioxia's CEO warned against sharp price increases, citing potential harm to AI investment and market growth. All three stocks had gained on Wednesday, with SK Hynix up 7.05%, Micron up 2.75%, and SanDisk up 1.51%. Broader market pressure from higher Treasury yields and oil prices also contributed to the decline.

$LLYHighAI 9/10

Eli Lilly (LLY) Stock Fair Value Edges Higher As Analysts Back GLP 1 Growth

Eli Lilly (LLY) received FDA approval for Inluriyo's combination therapy, boosting its breast cancer treatment options. Analysts at Berenberg upgraded LLY, citing growth prospects in weight-loss drugs and a robust pipeline. The company's fair value estimate increased to $1,325.39, with slight adjustments to revenue growth and net profit margin. Novartis' failed Lp(a) drug trial may impact similar programs at LLY and Amgen.

$NVOMed

Novo Nordisk (NVO) Secures Key EU Panel Backing For Child Growth Drug

Novo Nordisk (NVO) received a positive opinion from the European Medicines Agency's CHMP for Sogroya, a treatment for idiopathic short stature in children. If approved by the European Commission, Sogroya could become the first authorized therapy for this condition in the EU. This decision supports Novo Nordisk's efforts to expand its rare disease and pediatric endocrinology portfolio. The European Commission's decision is expected later in 2026.